Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Arvinas Inc

Healthcare US ARVN

7.42USD
-0.32(4.13%)

Last update at 2026-06-05T20:05:00Z

Day Range

7.407.81
LowHigh

52 Week Range

5.9014.51
LowHigh

Fundamentals

  • Previous Close 7.74
  • Market Cap682.06M
  • Volume649127
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-111.90000M
  • Revenue TTM262.60M
  • Revenue Per Share TTM3.70
  • Gross Profit TTM 262.60M
  • Diluted EPS TTM-1.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -80.50000M -198.30000M -366.40000M -251.00000M -191.00000M
Minority interest - - - - -
Net income -80.80000M -198.90000M -367.30000M -271.90000M -183.20000M
Selling general administrative 89.40M 165.40M 100.30M 79.60M 61.60M
Selling and marketing expenses - - 6.70M - -
Gross profit 257.40M 263.40M 78.50M 131.40M 46.70M
Reconciled depreciation 5.20M 6.60M 7.10M 8.20M 6.00M
Ebit -80.50000M -250.20000M -401.50000M -271.40000M -201.30000M
Ebitda -75.30000M -243.60000M -394.80000M -263.20000M -195.30000M
Depreciation and amortization 5.20M 6.60M 6.70M 8.20M 6.00M
Non operating income net other - - - 1.60M 4.40M
Operating income -114.90000M -250.20000M -401.50000M -263.20000M -195.30000M
Other operating expenses 377.50M 513.60M 480.00M 394.60M 242.00M
Interest expense - - - 12.00M 0.10M
Tax provision 0.30M 0.60M 10.10M 20.90M -
Interest income 38.40M 54.80M 32.30M 12.20M 1.90M
Net interest income 38.40M 54.80M 32.30M 12.20M 1.80M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.30M 0.60M 0.90M 20.90M -7.80000M
Total revenue 262.60M 263.40M 78.50M 131.40M 46.70M
Total operating expenses 372.30M 513.60M 480.00M 394.60M 242.00M
Cost of revenue 5.20M 6.60M 6.70M - -
Total other income expense net 34.40M 51.90M 35.10M 12.20M 4.30M
Discontinued operations - - - - -
Net income from continuing ops -80.80000M -198.90000M -295.40000M -282.50000M -191.00000M
Net income applicable to common shares - - - -282.50000M -191.00000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 717.90M 1091.40M 1304.60M 1268.80M 1581.60M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.90M 14.20M 6.50M 21.40M 19.70M
Total liab 284.00M 529.70M 644.60M 703.90M 799.90M
Total stockholder equity 433.90M 561.70M 660.00M 564.90M 781.70M
Deferred long term liab - - - - -
Other current liab 45.30M 57.20M 74.40M 69.00M 23.10M
Common stock 0.10M 0.10M 0.10M 0.10M -
Capital stock 0.00000M 0.10M 0.10M 0.10M 0.00000M
Retained earnings -1612.40000M -1531.60000M -1332.70000M -965.40000M -682.90000M
Other liab - - - 405.10M 534.30M
Good will - - - - -
Other assets - - 0.00000M 10.80M 0.10M
Cash 142.90M 100.50M 317.20M 81.30M 108.30M
Cash and equivalents - - - - -
Total current liabilities 142.50M 229.80M 257.10M 295.10M 261.70M
Current deferred revenue 71.30M 156.20M 163.00M 218.60M 206.20M
Net debt -134.40000M -90.80000M -313.80000M -75.80000M -103.30000M
Short term debt 1.70M 1.80M 2.10M 1.80M 1.10M
Short long term debt - - - - -
Short long term debt total 8.50M 9.70M 3.40M 5.50M 5.00M
Other stockholder equity 2045.00M 2092.20M 1995.70M 1549.40M 1469.20M
Property plant equipment - - - 13.40M 16.60M
Total current assets 700.70M 1067.30M 1280.20M 1240.20M 1552.50M
Long term investments - - - - -
Net tangible assets - - - 564.90M 781.70M
Short term investments 542.50M 938.90M 949.30M 1124.00M 1394.30M
Net receivables 6.40M 13.70M 7.20M 8.00M 25.70M
Long term debt 0.40M 0.60M 0.80M 1.00M 1.00M
Inventory - - - 5.50M 4.50M
Accounts payable 24.20M 13.20M 17.60M 5.70M 31.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.20M 1.00M -3.10000M -19.20000M -4.60000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.10M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -965.40000M -682.90000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.80M 8.10M 10.40M 10.80M 12.50M
Deferred long term asset charges - - - - -
Non current assets total 17.20M 24.10M 24.40M 28.60M 29.10M
Capital lease obligations 8.50M 9.10M 2.40M 4.50M 4.00M
Long term debt total - - - 1.00M 1.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 409.50M 34.70M 276.60M 249.60M -1308.90000M
Change to liabilities - - - 20.20M 719.20M
Total cashflows from investing activities 407.60M 34.70M 203.50M 242.80M -1313.60000M
Net borrowings -0.20000M -0.40000M 0.00000M - -
Total cash from financing activities -91.40000M 7.90M 374.70M 4.70M 278.60M
Change to operating activities - - - - -26.90000M
Net income -80.80000M -198.90000M -367.30000M -282.50000M -191.00000M
Change in cash 42.40M -216.70000M 230.40M -26.00000M -475.60000M
Begin period cash flow 100.50M 317.20M 86.80M 112.80M 588.40M
End period cash flow 142.90M 100.50M 317.20M 86.80M 112.80M
Total cash from operating activities -273.80000M -259.30000M -347.80000M -273.50000M 559.40M
Issuance of capital stock 0.00000M 0.00000M 37.10M 0.00000M 264.60M
Depreciation 5.20M 6.60M 6.70M 8.20M 6.00M
Other cashflows from investing activities - 0.10M - - -
Dividends paid - - - - -
Change to inventory - - - - -26.90000M
Change to account receivables 7.30M -5.70000M 0.80M 14.00M -14.00000M
Sale purchase of stock -91.90000M 0.00000M 0.00000M 4.70M 14.00M
Other cashflows from financing activities -91.40000M 8.30M -12.50000M 242.80M 14.00M
Change to netincome - - - 75.50M 65.70M
Capital expenditures 1.90M 1.80M 2.90M 6.80M 4.70M
Change receivables - - - 17.70M -17.30000M
Cash flows other operating - - - -116.40000M 668.30M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -26.00000M -475.60000M
Change in working capital -233.70000M -140.60000M -44.40000M -82.60000M 678.30M
Stock based compensation 44.00M 88.20M 71.60M 75.50M 57.10M
Other non cash items -8.50000M -14.60000M -14.40000M 7.90M 9.80M
Free cash flow -275.70000M -261.10000M -350.70000M -280.30000M 554.70M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARVN
Arvinas Inc		 -0.32 4.13% 7.42 - 17.86 2.60 1.59 0.06 -1.6185
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Inc

5 Science Park, New Haven, CT, United States, 06511

Key Executives

Name Title Year Born
Dr. John G. Houston Ph.D. CEO, Pres & Director 1960
Mr. Sean A. Cassidy CPA, CPA, M.B.A. CFO & Treasurer 1970
Dr. Ian Taylor Ph.D. Chief Scientific Officer 1962
Dr. Ronald A. Peck Chief Medical Officer NA
Mr. Jeff Boyle VP of Investor Relations NA
Mr. Matthew Batters J.D. Gen. Counsel & Corp. Sec. 1975
Dr. Randy Teel Ph.D. Sr. VP of Corp. & Bus. Devel. 1979
Mr. Steve Weiss Sr. VP & Chief HR Officer 1970
Dr. John A. Grosso Ph.D. Sr. VP of R&D Technical Operations 1957
Ms. Angela M. Cacace Ph.D. Sr. VP of Neuroscience & Platform Biology 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.